Amgen heads into mid-June with both its short sellers and its options traders moving in the same direction — away from bearish conviction.
The short rebuild that had been the dominant positioning story through late April and May has now reversed. Short interest dropped 5% in a single session on June 9, pulling the total to 12.5 million shares — 2.3% of the free float — down 7.5% from a month ago. That erases a meaningful chunk of the accumulation that ran from mid-April into early June. The borrow market corroborates the retreat: cost to borrow fell 27% on the week to just 0.41%, and availability is extraordinarily loose at nearly 5,900% — meaning there are roughly 59 shares available to lend for every one currently borrowed. There is no squeeze tension here. The ORTEX short score has edged down to 36.3, a modest reading that reinforces the picture of short sellers backing away rather than pressing.
Options positioning has shifted in the same direction. The put/call ratio fell to 0.80 by June 9, more than one standard deviation below its 20-day mean of 0.88 — the most call-skewed reading in several weeks. The prior note flagged that the defensive tone of late May had unwound; that unwind has continued and deepened. The ratio is now comfortably below its recent average and moving toward the lower end of its 52-week range of 0.62 to 1.11. Whatever hedging demand had built up through May has largely cleared.
The Street reflects a similar tension between caution and underlying conviction. Morgan Stanley's Terence Flynn raised his target to $340 this week while holding an Equal-Weight rating — a nudge higher but still below the current price of $344.57. That encapsulates the broader analyst setup: a consensus that sees limited near-term upside, with the mean target at $352.50, but an active bull minority (Piper Sandler at $427, UBS at $400) pointing to meaningful upside if pipeline catalysts deliver. The bull case rests on MariTide weight-loss data and Tezspire label expansion driving revenues well beyond 2026. Bears counter that the biosimilar portfolio is underperforming, oncology faces fresh competition, and cholesterol and migraine launches have disappointed. The P/E of 15.1x and EV/EBITDA near 10.7x are not demanding multiples for large-cap biotech, and both have drifted higher over the past 30 days as the stock recovered. The dividend factor score ranks in the 98th percentile — a reminder that income-oriented holders provide a durable floor for the name.
The institutional picture adds context without drama. Capital Research added over 3 million shares in its most recent report, and JP Morgan Asset Management added nearly 3.7 million — meaningful conviction from two active managers. BlackRock and State Street made smaller additions. The insider picture is less encouraging: ten executives including the CFO and CTO all sold on May 7 at $331, a coordinated cluster that looks routine in size but is worth noting given the timing just ahead of the stock's subsequent recovery. The net 90-day insider position is modestly positive at roughly $5.8 million, but that reflects earlier buying outweighing recent small sells.
Among close peers, INCY surged 11.9% on the week while GILD fell 1.6% — a reminder that biopharma moves are increasingly stock-specific rather than sector-driven. VRTX and ABBV both tracked broadly in line with Amgen's 5% weekly gain.
Q2 results are scheduled for August 4 — the last two earnings prints produced a modest bounce (+2.2% one-day) and a mild decline (-2.4%), so the historical reaction profile is contained. Between now and then, the primary watch items are any pipeline readouts on MariTide and whether the softening short position and call-skewed options market hold as the stock tests analyst consensus near $352.
See the live data behind this article on ORTEX.
Open AMGN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
